Sir Salimullah Medical College Journal

Sir Salimullah Med Coll J 2025; 33: 3-6

Review Article

DOI: https://doi.org/10.3329/ssmcj.v33i1.88647

# The Dual Nature of Blood: Transfusion-Mediated Immunomodulation in Modern Medicine

**Daanish Arefin Biswas**

**Article information**
**Received:** 12-11-2025
**Accepted:** 04-01-2026

**Cite this article:**
Biswas DA. The Dual Nature of Blood: Transfusion-Mediated Immunomodulation in Modern Medicine. Sir Salimullah Med Coll J 2025; 33(1): 3-6.

**Key words:**
Dual Nature of Blood, Transfusion, Mediated Immunomodulation, Modern Medicine

**Abstract**

*Allogeneic blood transfusion is a life-saving intervention that carries a significant, though often overlooked, immunologic consequence. Known as Transfusion-Mediated Immunomodulation (TRIM), this phenomenon represents a constellation of immune alterations in the recipient, ranging from beneficial tolerance to harmful immunosuppression and inflammation. Historically recognized for improving kidney transplant survival, the modern understanding of TRIM primarily characterizes it as a deleterious event that increases the risk of postoperative infections, organ failure, and potentially cancer recurrence. The pathophysiology has evolved from a focus on donor leukocytes to the complex "storage lesion," involving soluble biological mediators, extracellular vesicles, and mitochondrial DNA released during blood product storage. While universal leukoreduction has mitigated the risk, it has not eliminated it. This review delineates the key mechanisms driving TRIM, critically evaluates the strength of clinical evidence linking it to adverse outcomes, and champions Patient Blood Management as the cornerstone strategy for safeguarding patients against its effects.*

## Introduction:

The administration of allogeneic blood is one of the most common procedures in hospitalized patients, yet it is biologically comparable to a temporary, unmatched liquid transplant.[1] Unlike solid organ transplantation, this massive infusion of foreign cells and bioactive substances is typically administered without immuno-suppressive therapy, placing the recipient's immune system in a state of complex alert.

The concept of Transfusion-Mediated Immunomodulation (TRIM) emerged paradoxically half a century ago, when researchers observed that blood transfusions given prior to kidney transplantation significantly improved the survival of the graft.[1] This "beneficial" effect suggested that transfusion could induce a state of immune tolerance. However, as surgical and critical care advanced, this same immunosuppressive quality was re-evaluated as a potential hazard.[3] If transfusion could prevent the rejection of a foreign organ, could it also cripple a patient's ability to fight off a bacterial infection or surveil for cancer cells? The paradigm thus shifted, and TRIM is now largely viewed through the lens of a "two-hit" model: the patient's initial illness or injury provides the first hit that primes the immune system, and the immunomodulatory cargo of the transfused blood product delivers the second hit that can tip the balance toward clinical deterioration.[4]

## Methods:

This narrative review was prepared following a structured assessment of published literature. A targeted search of PubMed, MEDLINE and the

**Correspondence:** Dr. Daanish Arefin Biswas, Associate Professor, Department of Transfusion Medicine, Sir Salimullah Medical College, Mitford, Dhaka-1100, Bangladesh. email: dr.daanish.arefin@gmail.com; ORCID: 0000-0002-8083-1204

Cochrane Library was conducted using terms including "transfusion-related immunomodulation, " "TRIM," "mitochondrial DNA," "extracellular vesicles," "storage lesion," and "cancer recurrence." Literature published between 1973 and 2024 was reviewed, with specific emphasis on data generated after the widespread implementation of leukoreduction. Priority was given to randomized clinical trials (RCTs) and meta-analyses.

**Unraveling the Mechanisms: The Players in TRIM**

The mechanisms underlying TRIM are multifaceted, involving a dynamic interplay between cellular, soluble, and subcellular factors.

**The Cellular Legacy: Donor Leukocytes**

Before the widespread implementation of leukoreduction, donor white blood cells were considered the primary drivers of TRIM. These allogeneic cells could induce immune suppression through several pathways: causing recipient T-cells to become unresponsive (anergy), shifting the immune response from an attacking (Th1) to a suppressive (Th2) profile, and expanding populations of regulatory T-cells that actively dampen immunity.[5] While pre-storage leukoreduction has dramatically reduced this cellular burden, its legacy informs our understanding of residual immune dysregulation.[6]

**The Storage Lesion: A Ticking Clock in the Bag**

Even after leukocytes are removed, blood products are not inert. During storage, red blood cells and platelets undergo a series of metabolic and biochemical changes collectively known as the "storage lesion." As cells age in the bag, they release a potent cocktail of immunomodulatory substances into the supernatant:

- **Bioactive Lipids:** Molecules like lysophosphatidylcholines accumulate and can "prime" recipient neutrophils. When these primed neutrophils encounter a subsequent inflammatory signal (e.g., from surgery), they launch an exaggerated attack, causing collateral tissue damage, particularly in the lungs[7].
- **Soluble HLA:** These molecules shed from cell membranes can bind to and trigger apoptosis in recipient cytotoxic T-cells and Natural Killer (NK) cells, blunting crucial defenses against viruses and tumors.[8]
- **Cytokines:** Stored platelet concentrates, in particular, are a rich source of preformed cytokines, including potent immunosuppressants like TGF-α (4).

**The New Frontier: Subcellular and Metabolic Mediators**

Modern research has identified even smaller, filter-bypassing agents that contribute to TRIM:

- **Extracellular Vesicles (EVs):** These tiny, membrane-bound particles are shed from red blood cells and platelets during storage. They are far from inert debris; they carry functional cargo like microRNAs that can deliver signals to recipient immune cells, reprogramming them toward an anti-inflammatory state.[9]
- **Mitochondrial DNA (mtDNA):** A significant discovery is the role of mtDNA, which is released as red blood cells break down. Because of its bacterial ancestry, mtDNA is recognized by the recipient's immune system as a foreign invader, triggering a potent inflammatory response via pathways like the NLRP3 inflammasome, which can mimic sepsis.[10]
- **The Iron Hypothesis:** The transfusion of older red blood cell units introduces non-transferrin-bound iron and free heme. This free iron can serve as a nutrient for bacteria, promoting their growth, while also forcing macrophages to adopt a tolerant, anti-inflammatory phenotype, distracting them from their primary role of pathogen clearance.[11]

**Clinical Consequences: Separating Strong Signals from Controversy**

Linking these biological mechanisms to concrete patient outcomes is challenging, primarily due to "confounding by indication"—the fact that patients who receive transfusions are inherently sicker to begin with.

- **Postoperative Infections: The Strongest Link.** The most robust clinical evidence for TRIM is its association with an increased risk of nosocomial infections, including surgical site infections, pneumonia, and sepsis.[12] The risk appears dose-dependent, and the mechanism is thought to be a state of transient immunoparalysis, creating a window of vulnerability exactly when the patient is most exposed to pathogens.[5]

- **Cancer Recurrence: A Contentious Arena.** The fear that transfusion could fuel cancer recurrence—the "Vampire Effect"—is biologically plausible (13). If TRIM suppresses NK cell activity and promotes angiogenesis, it could theoretically facilitate metastatic spread. While numerous retrospective studies, especially in colorectal cancer, have supported this link[14], higher-quality evidence from randomized controlled trials in the leukoreduction era has been inconsistent[15]. The prevailing view is that any effect of transfusion is likely minor compared to the influence of tumor biology and the completeness of surgical resection, though avoiding unnecessary transfusions remains a prudent principle.
- **Organ Injury: The Inflammatory Face of TRIM.** Transfusion-related acute lung injury (TRALI) represents the inflammatory extreme of the TRIM spectrum. The accumulated bioactive lipids and mtDNA in stored blood can act as the second hit that activates primed neutrophils sequestered in the lung capillaries, leading to profound pulmonary edema and acute respiratory failure.[7, 10]

## Mitigating the Risk: A Focus on Patient Blood Management

Given that the safest unit of blood is the one never transfused, mitigation strategies focus squarely on reducing unnecessary exposure.

1. **Patient Blood Management (PBM) as the Cornerstone.** PBM is a multimodal, patient-centered approach built on three pillars.[16]
   - **Optimizing Hematopoiesis:** Diagnosing and treating anemia (e.g., with IV iron or erythropoietin) before elective surgery.
   - **Minimizing Blood Loss:** Employing meticulous surgical techniques, antifibrinolytic medications, and intraoperative cell salvage.
   - **Tolerating Anemia:** Adhering to evidence-based, restrictive transfusion thresholds (e.g., 7-8 g/dL in hemodynamically stable patients), which have been proven to be as safe as, if not safer than, liberal transfusion strategies.[17]
2. **Universal Leukoreduction (ULR).** The systematic removal of white blood cells from blood components before storage is the single most effective technological intervention against TRIM, having significantly reduced the incidence of febrile non-hemolytic reactions and HLA alloimmunization.[6]
3. **The Limited Utility of Other Strategies.**
   - **Blood Storage Age:** Large, randomized controlled trials have definitively shown that using fresh blood over standard-issue blood does not improve patient outcomes, making this an ineffective mitigation strategy.[18, 19]
   - **Product Washing:** Washing red blood cells to remove the storage lesion supernatant is effective but logistically cumbersome and reserved for specific clinical scenarios, such as in patients with severe allergic reactions.[20]

## Future Directions and Conclusion

The future of TRIM research lies in precision transfusion medicine. This includes identifying biomarkers to flag units with high immunomodulatory potential and developing novel additive solutions that can scavenge harmful substances or better preserve red blood cell integrity.[9, 10]

In conclusion, TRIM is an inherent and potent consequence of allogeneic blood transfusion. The field has matured from observing a curious effect in transplant patients to understanding a sophisticated interplay of immunologic mechanisms. While technological advances like leukoreduction have reduced the risk, the residual threat from the storage lesion persists.[6] For the clinician, this knowledge transforms blood from a simple commodity into a powerful biological drug with significant side effects. The most critical defense is not a better filter or a fresher unit, but a rigorous and unwavering commitment to the principles of Patient Blood Management[16], ensuring that every transfusion decision is both necessary and prudent.

## References

1. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21(6):327-48.
2. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978;299(15):799-803.
3. Blajchman MA. Immunomodulation and blood transfusion. Am J Ther. 2002;9(5):389-95.

4. Remy KE, Hall MW, Cholette J, et al. Mechanisms of red blood cell transfusion-related immunomodulation. Transfusion. 2018;58(3):804-15.

5. Muszynski JA, Spinella PC, Cholette JM, et al. Transfusion-related immunomodulation: review of the literature and implications for pediatric critical illness. Lancet Respir Med. 2017;5(4):332-344.

6. Seghatchian J. The "Residual Risk" of transfusion related immunomodulation (TRIM): An update. Transfus Apher Sci. 2020;59(2):102753.

7. Silliman CC, Moore EE, Kelher MR, Khan SY, Ghasabyan A, Chandler J. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion. 2011;51(12):2549-54.

8. Tormey CA, Hendrickson JE. Transfusion-related alloimmunization: the mechanisms and the markers. Transfusion. 2019;59(5):1823-1826.

9. Shopova G, Staneva G. Extracellular Vesicles in Blood Transfusion: A Double-Edged Sword. Int J Mol Sci. 2023;24(5):4452.

10. Hémon P, Arnaud AP, Goudable J, et al. Mitochondrial DNA in stored red blood cells: A mediator of transfusion complications? Transfus Med Rev. 2023;37(1):150722.

11. Goel R, Tobian AAR, Shaz BH. Non-infectious transfusion-associated adverse events and their mitigation strategies. Blood. 2019;133(17):1831-9.

12. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA. 2014;311(13):1317-26.

13. Cata JP, Wang H, Gottumukkala V, et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth. 2013;110(5):690-701.

14. McSorley ST, Tham A, Steele CW, et al. Perioperative blood transfusion is associated with disease recurrence and survival after colorectal cancer surgery: a systematic review and meta-analysis. Colorectal Dis. 2020;22(6):655-663.

15. Vamvakas EC. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. Transfus Med Rev. 2012;26(1):1-16.

16. Mueller MM, Van Remoortel H, Meybohm P, et al. Patient Blood Management: Recommendations from the 2018 Frankfurt Consensus Conference. JAMA. 2019;321(10):983-997.

17. Fominskiy E, Lomivorotov V, Belletti A, et al. Effect of Liberal vs Restrictive Transfusion Strategies on Freedom from Disability or Death After Cardiac Surgery: The TIRSS Randomized Clinical Trial. JAMA. 2023;330(15):1463-1473.

18. Cooper DJ, McQuilten ZK, Nichol A, et al. Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med. 2017;377(19):1858-67.

19. Lacroix J, Hébert PC, Fergusson DA, et al. Age of Transfused Blood in Critically Ill Adults. N Engl J Med. 2015;372(15):1410-8.

20. Lannan KL, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Transfusion immunomodulation—The case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis. 2013;50(1):61-68.